Gastrointestinal Cancer | Specialty

The OncLive Gastrointestinal Cancer condition center page is a comprehensive resource for clinical news and expert insights on various types of gastrointestinal (GI) cancers, including hepatocellular carcinoma, gastric cancer, pancreatic cancer, colorectal cancer, cholangiocarcinoma, esophageal cancer, and more. This page features news articles, interviews in written and video format, and podcasts that focus on unmet needs, treatment advances, and ongoing research in GI cancers.

Cetuximab Plus Pembrolizumab Well Tolerated in RAS Wild-Type mCRC

January 21st 2018

The combination of cetuximab and pembrolizumab was found to be well tolerated in patients with RAS wild-type metastatic colorectal cancer.

Lenvatinib Plus Pembrolizumab or Nivolumab Active in Intrahepatic Cholangiocarcinoma

January 21st 2018

Combining lenvatinib (Lenvima) with PD-1 inhibitors had promising efficacy in patients with advanced intrahepatic cholangiocarcinoma, according to preliminary data from a single-center study.

Regorafenib Before Cetuximab Improves Survival in mCRC

January 21st 2018

Sequencing regorafenib before cetuximab showed superior overall survival compared with the reverse sequence in patients with metastatic colorectal cancer following failure of standard chemotherapy.

Dr. Overman on Updated Findings With Nivolumab in Metastatic CRC

January 21st 2018

Michael J. Overman, MD, associate professor, department of Gastrointestinal Medical Oncology, The University of Texas MD Anderson Cancer Center, discusses the updated findings from CheckMate-142 in metastatic colorectal cancer during the 2018 Gastrointestinal Cancers Symposium.

Dr. Abou-Alfa Discusses Results of the CELESTIAL Trial in Advanced HCC

January 21st 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the results of the CELESTIAL trial in advanced hepatocellular carcinoma during the 2018 Gastrointestinal Cancers Symposium.

Nab-Paclitaxel/Gemcitabine Effective for Locally Advanced Pancreatic Cancer

January 20th 2018

Induction treatment with nab-paclitaxel plus gemcitabine demonstrated a time to treatment failure of 8.8 months for patients with newly diagnosed locally advanced pancreatic cancer.

Regorafenib Dose Escalation Superior in Metastatic CRC

January 20th 2018

Tanios Bekaii-Saab, MD, discusses the results and significance of the ReDOS study in metastatic colorectal cancer, as well as shared some insight on the Reverce trial.

Dr. Pishvaian Discusses Results of Entrectinib in Metastatic Pancreas Cancer

January 20th 2018

Michael Pishvaian, MD, PhD, director, Phase I Clinical Program, co-director of the Ruesch Center Pancreatic Cancer Program Medical Oncology, Otto J. Ruesch Center for the Cure of Gastrointestinal Cancer, Georgetown University Lombardi Comprehensive Cancer Center, discusses the results of a study of entrectinib in patients with pancreas cancer.

Dr. Catenacci on Results of Margetuximab Plus Pembrolizumab in Gastric/GEJ Cancer

January 20th 2018

Daniel Catenacci, MD, medical oncologist, assistant professor of medicine, Univeristy of Chicago Medicine, discusses margetuximab (MGAH22-10) plus pembrolizumab (Keytruda) as treatment for patients with advanced HER2-positive gastroesophageal junction (GEJ) or gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

Adding Ramucirumab to Frontline Chemo Does Not Improve Survival in Gastric Cancer

January 19th 2018

Adding ramucirumab to standard first-line chemotherapy significantly improved investigator-assessed progression-free survival compared with chemotherapy plus placebo in treatment-naive patients with HER2-negative gastric cancer.

Dr. Svensson on PD-1/PD-L1 Status in Esophageal and Gastric Adenocarcinoma

January 19th 2018

Maria Svensson, MD, Lund University, discusses the associations of PD-1 and PD-L1 expression with mismatch repair (MMR) status and prognosis in chemoradiotherapy-naïve esophageal and gastric adenocarcinoma during the 2018 Gastrointestinal Cancers Symposium.

Dr. Singh Discusses Study of Nivolumab in Patients With GIST

January 19th 2018

Arun S. Singh, MD, associate professor, UCLA David Geffen School of Medicine, discusses a phase II study of nivolumab (Opdivo) in patients with metastatic unresectable gastrointestinal stromal tumors (GIST) during the 2018 Gastrointestinal Cancers Symposium.

Ramucirumab/Durvalumab Combination Shows Antitumor Activity in Gastric and GEJ Cancer

January 19th 2018

The combination of the VEGFR-2 inhibitor ramucirumab plus the anti-PD-L1 agent durvalumab demonstrated antitumor activity in patients with previously treated advanced gastric or gastroesophageal junction adenocarcinoma.

Trastuzumab Deruxtecan Active in HER2-Expressing Gastric Cancer

January 19th 2018

The novel investigational HER2-targeting antibody-drug conjugate trastuzumab deruxtecan showed promising antitumor activity in heavily pretreated patients with HER2-expressing gastric cancer.

Classifying NETs Versus NECs in Gastrointestinal Cancer

January 18th 2018

Jennifer Eads, MD, discusses the classification of NETs versus NECs in gastrointestinal cancer.

Dr. O'Reilly on Areas of Research in Pancreatic Cancer

January 18th 2018

Eileen O’Reilly, MD, associate director for clinical research at Memorial Sloan Kettering Cancer Center discusses areas of research for patients with pancreatic cancer.

Pancreatic Ductal Carcinoma: Slow Progress for a Hard-to-Treat Cancer

January 17th 2018

Pancreatic ductal adenocarcinoma, which is considered incurable, accounts for more than 90% of pancreatic cancer cases.

Cabozantinib Improves OS, PFS in Advanced HCC

January 17th 2018

Treatment with cabozantinib improved median overall survival by 2.2 months compared with placebo for patients with previously treated advanced hepatocellular carcinoma.

Dr. Saltz Discusses FOLFIRINOX in Colorectal Cancer

January 17th 2018

Leonard Saltz, MD, executive director for Clinical Value & Sustainability, head, Colorectal Oncology Section, Memorial Sloan Kettering Cancer Center, discusses the option of FOLFIRINOX for the treatment of patients with metastatic colorectal cancer.

Dr. Abou-Alfa Discusses Treatment Options in Liver Cancer

January 17th 2018

Ghassan K. Abou-Alfa, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses treatment options in liver cancer.

NEXT PAGE
PREVIOUS PAGE